Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05423327 · ClinicalTrials.gov registry record · NA
Genetic Data Collection in Adult Participants to Identify Genetic Variants of Known Importance in Non-alcoholic Steatohepatitis (NASH)
A NA study, sponsored by Regeneron Pharmaceuticals.
- Terminated
- Registry status
- NA
- Development phase
- 5,311
- Enrollment target
NCT05423327: Clinical Trial NA study, sponsored by Regeneron Pharmaceuticals.
NCT05423327 is a NA study that was terminated before completion, run by Regeneron Pharmaceuticals. The registered enrollment target is 5,311 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (278% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05423327, a NA study, was terminated before completion, sponsored by Regeneron Pharmaceuticals.
- TERMINATED
- Registry status
- NA
- Development phase
- 5,311 participants
- Enrollment target
Study Summary
Collection of clinical and genetic data to help identify individuals that carry genetic variants of known importance in Non-alcoholic Steatohepatitis (NASH)
Interventions
- PROCEDURE No Intervention
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,311 participants |
| Start Date | 2021-12-09 |
| Est. Completion | 2022-10-27 |
| Phase | NA |
Why NCT05423327 stopped before completion
NCT05423327 is an interventional study that assigns participants to a tested intervention. Its 5,311 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (278% higher).
The record links to 0 conditions, and to 1 intervention - of which No Intervention is the first listed.
NCT05423327 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05423327 about?
NCT05423327 is a clinical study titled "Genetic Data Collection in Adult Participants to Identify Genetic Variants of Known Importance in Non-alcoholic Steatohepatitis (NASH)". Collection of clinical and genetic data to help identify individuals that carry genetic variants of known importance in Non-alcoholic Steatohepatitis (NASH)
What is the current status of trial NCT05423327?
This trial is currently terminated. It is a NA study. The enrollment target is 5,311 participants. The study started on 2021-12-09. Estimated completion is 2022-10-27.
What interventions are being tested in trial NCT05423327?
The interventions under investigation include: No Intervention (PROCEDURE).
Who is sponsoring clinical trial NCT05423327?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05423327's enrollment target sits among peer trials
5,311 24th of 2000 higher than 1,977 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05373771 · 5,328 participants · NA
Sickle Cell Improvement: Enhancing Care in the Emergency Department
- NCT05836987 · 5,350 participants · Phase 3
The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation
- NCT06506344 · 5,250 participants · NA
Syncing Screening and Services for Suicide Prevention Across Health and Justice Systems
- NCT05722769 · 5,408 participants · NA
CSTOP Now! Child Sex Trafficking Stops With You
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI